C-Reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders
References (16)
- et al.
Serum alpha-1-acid glycoprotein in chronic ulcerative colitis
Gastroenterology
(1969) C-reactive protein fifty years on
Lancet
(1981)Aspects of the acute phase response. The C-reactive protein system
- et al.
Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management
Gut
(1979) - et al.
C-reactive protein usefulness in diagnosis and survey for Crohn's disease and ulcerative colitis
Gastroenterol Clin Biol
(1979) - et al.
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis
Eur J Clin Invest
(1982) Factors in the management of Crohn's disease: a discussion paper
J R Soc Med
(1981)- et al.
Serum orosomucoid in ulcerative colitis
Scand J Gastroenterol
(1976)
Cited by (84)
Assessing Severity of Disease in Patients with Ulcerative Colitis
2020, Gastroenterology Clinics of North AmericaCitation Excerpt :ESR especially is nonspecific and does not change as rapidly as CRP does, further limiting its utility.18,19 Importantly, historical studies have shown that up to 50% of patients with active disease may not have increased levels of CRP.20,21 Cutoffs of less than 5 to 6 mg/L have been proposed for CRP, with the main limitation of this test being its decreased sensitivity and negative predictive value; that is, a large proportion of patients with mild disease may have normal CRP levels.22,23
AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)
2019, GastroenterologyCitation Excerpt :Erythrocyte sedimentation rate (ESR) is a measure of blood viscosity and is a surrogate marker of inflammation. There were 4 studies39,42,51,60 that provided test accuracy data for erythrocyte sedimentation rate at cutoff 10 to 15 mm/h among 353 participants and 1 additional study including 74 participants where no cutoff was reported.42 Among the 4 studies, sensitivity estimates ranged from 0.54 to 0.78, and specificity ranged from 0.46 to 0.95 (low-quality evidence, very serious issues of limitation in study design) (Appendix 3, eTable 6, Appendix 4, and eFigures 6.1–6.4).
Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials
2013, Journal of Crohn's and ColitisSelected Cytokines and Metalloproteinases in Inflammatory Bowel Disease
2024, International Journal of Molecular SciencesEffectiveness of Leucine-Rich Alpha-2 Glycoprotein for a Pediatric Patient with Crohn Disease
2023, Indian Journal of PediatricsLaboratory evaluation of inflammatory bowel disease
2023, Pediatric Inflammatory Bowel Disease